GlobeNewswire

SCRUM ALLIANCE® AND SCRUM INC. ANNOUNCE PARTNERSHIP ON SCRUM@SCALE® FRAMEWORK FOR ORGANIZATIONAL AGILE TRANSFORMATION

Dela

Scrum Alliance launches joint venture with Dr. Jeff Sutherland's Scrum@Scale LLC.

 

DENVER, CO, and CAMBRIDGE, MA, April 16, 2018 (GLOBE NEWSWIRE) -- Scrum Alliance® and Scrum Inc. are launching a new joint venture to train, coach, and promote Dr. Jeff Sutherland's framework for Agile transformation via scaling Scrum across entire organizations.

Scrum Alliance is the largest and most established Scrum certifying body and professional association of Agile practitioners in the world. With more than 500,000 certified practitioners, Scrum Alliance is dedicated to helping individuals and organizations transform their world of work. Scrum Inc. founded by Dr. Jeff Sutherlrand the co-creator of Scrum is the world's leading authority of implementing Scrum. They have helped hundreds of organizations, from Fortune 100 companies to start-ups, fundamentally reshape themselves to dramatically increase productivity and drive growth.

Scrum@Scale ®  is the natural extension of the Scrum framework. It is designed to deliver business agility across an entire organization: all departments, products, and services. No matter the industry, Scrum@Scale makes every team a Scrum team and transforms organizations into market-disrupting forces. Dr. Sutherland, one of the original signers of the Agile Manifesto, recently stepped down from his position as CEO of Scrum Inc. to focus on the training and implementation of Scrum@Scale.

"Scrum@Scale is a framework where networks of Scrum teams can efficiently address complex problems while creatively delivering products of the highest possible value," said Sutherland. "We look forward to working with Scrum Alliance and their tremendous networks of trainers, coaches, and members to promote this new way of building healthy, high-functioning organizations."

"We believe Scrum@Scale offers organizations a strong solution for a Scrum scaling framework," said Scrum Alliance Board Member Lisa Hershman. "We are so excited to offer our community of trainers and coaches access to the Scrum@Scale education tools and framework solutions for a new phase in our mission of transforming the world of work."

As the world becomes more Agile, more businesses search for ways to incorporate scaling solutions in their organizations. Scrum Alliance and Scrum Inc. share a vision to help as many organizations as possible practice "good Scrum" and change the world of work. Scrum@Scale achieves this goal through setting up a "minimum viable bureaucracy" that extends the benefits of single Scrum team across the organization.

The partnership was announced at the Scrum Alliance 2018 North American Global Scrum Gathering® in Minneapolis. The sold-out event was the largest Global Scrum Gathering in Scrum Alliance history.

To learn more about Scrum@Scale, read the open source Scrum@Scale Guide, which is being translated into dozens of additional languages.

###

About Scrum Alliance

Founded in 2001, Scrum Alliance® is the largest, most established and influential professional membership and certification organization in the Agile community. Scrum Alliance is a nonprofit association with more than 500,000 certified practitioners worldwide. Its vision is to help "Transform the World of Work" with a mission to guide and inspire individuals, leaders, and organizations with practices, principles, and values that create workplaces that are joyful, prosperous, and sustainable. For more information, please visit scrumalliance.org.

Connect with us on social media at:

https://twitter.com/ScrumAlliance

https://www.facebook.com/scrumalliance

https://www.linkedin.com/company/scrum-alliance

https://www.youtube.com/user/scrumalliance

About Scrum Inc.

Scrum Inc., the world's leading authority on Scrum, provides training, consulting, and coaching that enables organizations to deliver value faster and reduce waste. Scrum Inc. was founded by Dr. Jeff Sutherland, the co-creator of Scrum, and has helped hundreds of organizations, from Fortune 100 companies to start-ups, fundamentally reshape themselves to dramatically increase productivity and drive growth. Scrum Inc. is the preeminent thought leader in the Agile community and publishes scientific papers, case studies, blogs, online educational content, and management and leadership books such as our recent best-selling Scrum: The Art of Doing Twice the Work in Half the Time

Visit scruminc.com to learn about our consulting servicestraining courses, and online learning resources. Follow us on Twitter @ScrumInc, LinkedIn, or visit our blog.

About Scrum@Scale LLC

Scrum@Scale is a training and certification company that provides Scrum Practitioners with the most current learning thy need to Scale Scrum, to teach others the Scrum@Scale framework, and to address complex problems using the framework, while delivering high-value products and services. We do this by delivering rigorous training, openly sharing knowledge, and being the go-to thought leader regarding organizational transformation. Learn more at scrumatscale.com.

Scrum@Scale LLC is a joint venture between Scrum Inc. and Scrum Alliance, two of the world's leading authorities on Scrum.

 

 

Heather Leigh
Scrum Alliance.
720-443-7314
hleigh@scrumalliance.org

Veronica Ruiz
Scrum Inc. Public Relations
718-781-4168
veronica.ruiz@scruminc.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Scrum Alliance via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum